Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

• Status: Withdrawn
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Treatments: Antibodies; Daclizumab; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Mycophenolate mofetil; Mycophenolic Acid; Rho(D) Immune Globulin; Tacrolimus

Criteria

Inclusion Criteria:

• Patient is a male or female.

• Age of 18-75.

• Patient must have the ability to provide informed consent.

• Positive cross-match with intended donor and/or ABO incompatible with intended donor.

Exclusion Criteria:

• Patients under the age of 18 or over the age of 75.

• Women that are currently pregnant.

• Patient has a history of any illness that, in the opinion of the investigator(s), might confound the results of the study or pose additional risk to the patient.